Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2013-01, Vol.31 (1), p.95-103 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 103 |
|---|---|
| container_issue | 1 |
| container_start_page | 95 |
| container_title | Journal of clinical oncology |
| container_volume | 31 |
| creator | GRÖSCHEL, Stefan SCHLENK, Richard F GERMING, Ulrich SCHMIDT-WOLF, Ingo G. H BERNA BEVERLOO, H SCHUURHUIS, Gerrit J OSSENKOPPELE, Gert J SCHLEGELBERGER, Brigitte VERDONCK, Leo F VELLENGA, Edo VERHOEF, Gregor VANDENBERGHE, Peter ENGELMANN, Jan PABST, Thomas BARGETZI, Mario KRAUTER, Jürgen GANSER, Arnold VALK, Peter J. M LÖWENBERG, Bob DÖHNER, Konstanze DÖHNER, Hartmut DELWEL, Ruud ROCKOVA, Veronika TELEANU, Veronica KÜHN, Michael W. M EIWEN, Karina ERPELINCK, Claudia HAVERMANS, Marije LÜBBERT, Michael |
| description | To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements.
We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis.
We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS; hazard ratio [HR], 2.06; P = .003), relapse-free survival (HR, 2.28; P = .002), and event-free survival (HR, 1.79; P = .009). EVI1(+) AMLs with t(11q23) in first complete remission (CR) had a significantly better outcome after allogeneic transplantation compared with other consolidation therapies (5-year OS, 54.7% v 0%; Mantel-Byar, P = .0006). EVI1(-) t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequently had additional trisomy 8 (39.6%; P < .001). Among t(9;11) AMLs, EVI1(+) again was the sole independent adverse prognostic factor for survival.
Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR. |
| doi_str_mv | 10.1200/JCO.2011.41.5505 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273738424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273738424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-f5f6a4e1346fab789df5621395371d5e4e27f79edafff4f4289542e23f3297c63</originalsourceid><addsrcrecordid>eNp1kTtvE0EURlcIRJxAT4WmACnNOvP0rOmMbZwQB0cYIrrRePeOPWF3x8yD4B_M_2CNDVRUtznnk65Olr0guE8oxhfvx4s-xYT0OekLgcWjrEcElbmUQjzOelgympOCfTnJTkO4x5jwgomn2QllGBeM0F72cwIe1qnWESo0_bH1EIJ1LXIGTe-uCJqAsS0EpNGtcx7derduXYi2RMu0ChD34M18nn8E7b1u193KqEwR0M0OamcrNIf0FRqrwxs0QsuYqt1eiRtAM_CNbvNRCtFb3f7HOzoz79IW6bb6rU5SLDf5W6jXnZgvH2wI6HJxt_hwsRxdX6Oxc1vwOtrvcBCfZU-MrgM8P96z7PO76afxZT5fzK7Go3lecixiboQZaA6E8YHRK1kMKyMGlLChYJJUAjhQaeQQKm2M4YbTYig4BcoMo0NZDthZdn7Y3Xr3LUGIqrGhhLrWLbgUFKGSSVZwyjsUH9DSuxA8GLX1ttF-pwhW-7iqi6v2cRUnah-3U14e19Oqgeqv8KdmB7w-AjqUujZdkNKGf5zEUnLOOu7VgdvY9ebBelCh0XXdzVJ1XzpGFFHdz78AjNa6_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273738424</pqid></control><display><type>article</type><title>Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>GRÖSCHEL, Stefan ; SCHLENK, Richard F ; GERMING, Ulrich ; SCHMIDT-WOLF, Ingo G. H ; BERNA BEVERLOO, H ; SCHUURHUIS, Gerrit J ; OSSENKOPPELE, Gert J ; SCHLEGELBERGER, Brigitte ; VERDONCK, Leo F ; VELLENGA, Edo ; VERHOEF, Gregor ; VANDENBERGHE, Peter ; ENGELMANN, Jan ; PABST, Thomas ; BARGETZI, Mario ; KRAUTER, Jürgen ; GANSER, Arnold ; VALK, Peter J. M ; LÖWENBERG, Bob ; DÖHNER, Konstanze ; DÖHNER, Hartmut ; DELWEL, Ruud ; ROCKOVA, Veronika ; TELEANU, Veronica ; KÜHN, Michael W. M ; EIWEN, Karina ; ERPELINCK, Claudia ; HAVERMANS, Marije ; LÜBBERT, Michael</creator><creatorcontrib>GRÖSCHEL, Stefan ; SCHLENK, Richard F ; GERMING, Ulrich ; SCHMIDT-WOLF, Ingo G. H ; BERNA BEVERLOO, H ; SCHUURHUIS, Gerrit J ; OSSENKOPPELE, Gert J ; SCHLEGELBERGER, Brigitte ; VERDONCK, Leo F ; VELLENGA, Edo ; VERHOEF, Gregor ; VANDENBERGHE, Peter ; ENGELMANN, Jan ; PABST, Thomas ; BARGETZI, Mario ; KRAUTER, Jürgen ; GANSER, Arnold ; VALK, Peter J. M ; LÖWENBERG, Bob ; DÖHNER, Konstanze ; DÖHNER, Hartmut ; DELWEL, Ruud ; ROCKOVA, Veronika ; TELEANU, Veronica ; KÜHN, Michael W. M ; EIWEN, Karina ; ERPELINCK, Claudia ; HAVERMANS, Marije ; LÜBBERT, Michael</creatorcontrib><description>To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements.
We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis.
We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS; hazard ratio [HR], 2.06; P = .003), relapse-free survival (HR, 2.28; P = .002), and event-free survival (HR, 1.79; P = .009). EVI1(+) AMLs with t(11q23) in first complete remission (CR) had a significantly better outcome after allogeneic transplantation compared with other consolidation therapies (5-year OS, 54.7% v 0%; Mantel-Byar, P = .0006). EVI1(-) t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequently had additional trisomy 8 (39.6%; P < .001). Among t(9;11) AMLs, EVI1(+) again was the sole independent adverse prognostic factor for survival.
Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2011.41.5505</identifier><identifier>PMID: 23008312</identifier><language>eng</language><publisher>Alexandria, VA: American Society of Clinical Oncology</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Chromosome Aberrations ; Chromosomes, Human, Pair 11 - genetics ; Chromosomes, Human, Pair 9 - genetics ; DNA-Binding Proteins - genetics ; Female ; Follow-Up Studies ; Gene Rearrangement ; Hematologic and hematopoietic diseases ; Histone-Lysine N-Methyltransferase ; Humans ; Karyotyping ; Leukemia, Myeloid, Acute - classification ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - mortality ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; MDS1 and EVI1 Complex Locus Protein ; Medical sciences ; Middle Aged ; Myeloid-Lymphoid Leukemia Protein - genetics ; Neoplasm Staging ; Prognosis ; Prospective Studies ; Proto-Oncogenes - genetics ; Remission Induction ; Survival Rate ; Transcription Factors - genetics ; Translocation, Genetic - genetics ; Tumors ; Young Adult</subject><ispartof>Journal of clinical oncology, 2013-01, Vol.31 (1), p.95-103</ispartof><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-f5f6a4e1346fab789df5621395371d5e4e27f79edafff4f4289542e23f3297c63</citedby><cites>FETCH-LOGICAL-c405t-f5f6a4e1346fab789df5621395371d5e4e27f79edafff4f4289542e23f3297c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3716,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27077443$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23008312$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GRÖSCHEL, Stefan</creatorcontrib><creatorcontrib>SCHLENK, Richard F</creatorcontrib><creatorcontrib>GERMING, Ulrich</creatorcontrib><creatorcontrib>SCHMIDT-WOLF, Ingo G. H</creatorcontrib><creatorcontrib>BERNA BEVERLOO, H</creatorcontrib><creatorcontrib>SCHUURHUIS, Gerrit J</creatorcontrib><creatorcontrib>OSSENKOPPELE, Gert J</creatorcontrib><creatorcontrib>SCHLEGELBERGER, Brigitte</creatorcontrib><creatorcontrib>VERDONCK, Leo F</creatorcontrib><creatorcontrib>VELLENGA, Edo</creatorcontrib><creatorcontrib>VERHOEF, Gregor</creatorcontrib><creatorcontrib>VANDENBERGHE, Peter</creatorcontrib><creatorcontrib>ENGELMANN, Jan</creatorcontrib><creatorcontrib>PABST, Thomas</creatorcontrib><creatorcontrib>BARGETZI, Mario</creatorcontrib><creatorcontrib>KRAUTER, Jürgen</creatorcontrib><creatorcontrib>GANSER, Arnold</creatorcontrib><creatorcontrib>VALK, Peter J. M</creatorcontrib><creatorcontrib>LÖWENBERG, Bob</creatorcontrib><creatorcontrib>DÖHNER, Konstanze</creatorcontrib><creatorcontrib>DÖHNER, Hartmut</creatorcontrib><creatorcontrib>DELWEL, Ruud</creatorcontrib><creatorcontrib>ROCKOVA, Veronika</creatorcontrib><creatorcontrib>TELEANU, Veronica</creatorcontrib><creatorcontrib>KÜHN, Michael W. M</creatorcontrib><creatorcontrib>EIWEN, Karina</creatorcontrib><creatorcontrib>ERPELINCK, Claudia</creatorcontrib><creatorcontrib>HAVERMANS, Marije</creatorcontrib><creatorcontrib>LÜBBERT, Michael</creatorcontrib><title>Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements.
We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis.
We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS; hazard ratio [HR], 2.06; P = .003), relapse-free survival (HR, 2.28; P = .002), and event-free survival (HR, 1.79; P = .009). EVI1(+) AMLs with t(11q23) in first complete remission (CR) had a significantly better outcome after allogeneic transplantation compared with other consolidation therapies (5-year OS, 54.7% v 0%; Mantel-Byar, P = .0006). EVI1(-) t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequently had additional trisomy 8 (39.6%; P < .001). Among t(9;11) AMLs, EVI1(+) again was the sole independent adverse prognostic factor for survival.
Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Chromosome Aberrations</subject><subject>Chromosomes, Human, Pair 11 - genetics</subject><subject>Chromosomes, Human, Pair 9 - genetics</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Rearrangement</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Histone-Lysine N-Methyltransferase</subject><subject>Humans</subject><subject>Karyotyping</subject><subject>Leukemia, Myeloid, Acute - classification</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>MDS1 and EVI1 Complex Locus Protein</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myeloid-Lymphoid Leukemia Protein - genetics</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Proto-Oncogenes - genetics</subject><subject>Remission Induction</subject><subject>Survival Rate</subject><subject>Transcription Factors - genetics</subject><subject>Translocation, Genetic - genetics</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kTtvE0EURlcIRJxAT4WmACnNOvP0rOmMbZwQB0cYIrrRePeOPWF3x8yD4B_M_2CNDVRUtznnk65Olr0guE8oxhfvx4s-xYT0OekLgcWjrEcElbmUQjzOelgympOCfTnJTkO4x5jwgomn2QllGBeM0F72cwIe1qnWESo0_bH1EIJ1LXIGTe-uCJqAsS0EpNGtcx7derduXYi2RMu0ChD34M18nn8E7b1u193KqEwR0M0OamcrNIf0FRqrwxs0QsuYqt1eiRtAM_CNbvNRCtFb3f7HOzoz79IW6bb6rU5SLDf5W6jXnZgvH2wI6HJxt_hwsRxdX6Oxc1vwOtrvcBCfZU-MrgM8P96z7PO76afxZT5fzK7Go3lecixiboQZaA6E8YHRK1kMKyMGlLChYJJUAjhQaeQQKm2M4YbTYig4BcoMo0NZDthZdn7Y3Xr3LUGIqrGhhLrWLbgUFKGSSVZwyjsUH9DSuxA8GLX1ttF-pwhW-7iqi6v2cRUnah-3U14e19Oqgeqv8KdmB7w-AjqUujZdkNKGf5zEUnLOOu7VgdvY9ebBelCh0XXdzVJ1XzpGFFHdz78AjNa6_A</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>GRÖSCHEL, Stefan</creator><creator>SCHLENK, Richard F</creator><creator>GERMING, Ulrich</creator><creator>SCHMIDT-WOLF, Ingo G. H</creator><creator>BERNA BEVERLOO, H</creator><creator>SCHUURHUIS, Gerrit J</creator><creator>OSSENKOPPELE, Gert J</creator><creator>SCHLEGELBERGER, Brigitte</creator><creator>VERDONCK, Leo F</creator><creator>VELLENGA, Edo</creator><creator>VERHOEF, Gregor</creator><creator>VANDENBERGHE, Peter</creator><creator>ENGELMANN, Jan</creator><creator>PABST, Thomas</creator><creator>BARGETZI, Mario</creator><creator>KRAUTER, Jürgen</creator><creator>GANSER, Arnold</creator><creator>VALK, Peter J. M</creator><creator>LÖWENBERG, Bob</creator><creator>DÖHNER, Konstanze</creator><creator>DÖHNER, Hartmut</creator><creator>DELWEL, Ruud</creator><creator>ROCKOVA, Veronika</creator><creator>TELEANU, Veronica</creator><creator>KÜHN, Michael W. M</creator><creator>EIWEN, Karina</creator><creator>ERPELINCK, Claudia</creator><creator>HAVERMANS, Marije</creator><creator>LÜBBERT, Michael</creator><general>American Society of Clinical Oncology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130101</creationdate><title>Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group</title><author>GRÖSCHEL, Stefan ; SCHLENK, Richard F ; GERMING, Ulrich ; SCHMIDT-WOLF, Ingo G. H ; BERNA BEVERLOO, H ; SCHUURHUIS, Gerrit J ; OSSENKOPPELE, Gert J ; SCHLEGELBERGER, Brigitte ; VERDONCK, Leo F ; VELLENGA, Edo ; VERHOEF, Gregor ; VANDENBERGHE, Peter ; ENGELMANN, Jan ; PABST, Thomas ; BARGETZI, Mario ; KRAUTER, Jürgen ; GANSER, Arnold ; VALK, Peter J. M ; LÖWENBERG, Bob ; DÖHNER, Konstanze ; DÖHNER, Hartmut ; DELWEL, Ruud ; ROCKOVA, Veronika ; TELEANU, Veronica ; KÜHN, Michael W. M ; EIWEN, Karina ; ERPELINCK, Claudia ; HAVERMANS, Marije ; LÜBBERT, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-f5f6a4e1346fab789df5621395371d5e4e27f79edafff4f4289542e23f3297c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Chromosome Aberrations</topic><topic>Chromosomes, Human, Pair 11 - genetics</topic><topic>Chromosomes, Human, Pair 9 - genetics</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Rearrangement</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Histone-Lysine N-Methyltransferase</topic><topic>Humans</topic><topic>Karyotyping</topic><topic>Leukemia, Myeloid, Acute - classification</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>MDS1 and EVI1 Complex Locus Protein</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myeloid-Lymphoid Leukemia Protein - genetics</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Proto-Oncogenes - genetics</topic><topic>Remission Induction</topic><topic>Survival Rate</topic><topic>Transcription Factors - genetics</topic><topic>Translocation, Genetic - genetics</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GRÖSCHEL, Stefan</creatorcontrib><creatorcontrib>SCHLENK, Richard F</creatorcontrib><creatorcontrib>GERMING, Ulrich</creatorcontrib><creatorcontrib>SCHMIDT-WOLF, Ingo G. H</creatorcontrib><creatorcontrib>BERNA BEVERLOO, H</creatorcontrib><creatorcontrib>SCHUURHUIS, Gerrit J</creatorcontrib><creatorcontrib>OSSENKOPPELE, Gert J</creatorcontrib><creatorcontrib>SCHLEGELBERGER, Brigitte</creatorcontrib><creatorcontrib>VERDONCK, Leo F</creatorcontrib><creatorcontrib>VELLENGA, Edo</creatorcontrib><creatorcontrib>VERHOEF, Gregor</creatorcontrib><creatorcontrib>VANDENBERGHE, Peter</creatorcontrib><creatorcontrib>ENGELMANN, Jan</creatorcontrib><creatorcontrib>PABST, Thomas</creatorcontrib><creatorcontrib>BARGETZI, Mario</creatorcontrib><creatorcontrib>KRAUTER, Jürgen</creatorcontrib><creatorcontrib>GANSER, Arnold</creatorcontrib><creatorcontrib>VALK, Peter J. M</creatorcontrib><creatorcontrib>LÖWENBERG, Bob</creatorcontrib><creatorcontrib>DÖHNER, Konstanze</creatorcontrib><creatorcontrib>DÖHNER, Hartmut</creatorcontrib><creatorcontrib>DELWEL, Ruud</creatorcontrib><creatorcontrib>ROCKOVA, Veronika</creatorcontrib><creatorcontrib>TELEANU, Veronica</creatorcontrib><creatorcontrib>KÜHN, Michael W. M</creatorcontrib><creatorcontrib>EIWEN, Karina</creatorcontrib><creatorcontrib>ERPELINCK, Claudia</creatorcontrib><creatorcontrib>HAVERMANS, Marije</creatorcontrib><creatorcontrib>LÜBBERT, Michael</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GRÖSCHEL, Stefan</au><au>SCHLENK, Richard F</au><au>GERMING, Ulrich</au><au>SCHMIDT-WOLF, Ingo G. H</au><au>BERNA BEVERLOO, H</au><au>SCHUURHUIS, Gerrit J</au><au>OSSENKOPPELE, Gert J</au><au>SCHLEGELBERGER, Brigitte</au><au>VERDONCK, Leo F</au><au>VELLENGA, Edo</au><au>VERHOEF, Gregor</au><au>VANDENBERGHE, Peter</au><au>ENGELMANN, Jan</au><au>PABST, Thomas</au><au>BARGETZI, Mario</au><au>KRAUTER, Jürgen</au><au>GANSER, Arnold</au><au>VALK, Peter J. M</au><au>LÖWENBERG, Bob</au><au>DÖHNER, Konstanze</au><au>DÖHNER, Hartmut</au><au>DELWEL, Ruud</au><au>ROCKOVA, Veronika</au><au>TELEANU, Veronica</au><au>KÜHN, Michael W. M</au><au>EIWEN, Karina</au><au>ERPELINCK, Claudia</au><au>HAVERMANS, Marije</au><au>LÜBBERT, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>31</volume><issue>1</issue><spage>95</spage><epage>103</epage><pages>95-103</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements.
We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis.
We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS; hazard ratio [HR], 2.06; P = .003), relapse-free survival (HR, 2.28; P = .002), and event-free survival (HR, 1.79; P = .009). EVI1(+) AMLs with t(11q23) in first complete remission (CR) had a significantly better outcome after allogeneic transplantation compared with other consolidation therapies (5-year OS, 54.7% v 0%; Mantel-Byar, P = .0006). EVI1(-) t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequently had additional trisomy 8 (39.6%; P < .001). Among t(9;11) AMLs, EVI1(+) again was the sole independent adverse prognostic factor for survival.
Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR.</abstract><cop>Alexandria, VA</cop><pub>American Society of Clinical Oncology</pub><pmid>23008312</pmid><doi>10.1200/JCO.2011.41.5505</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2013-01, Vol.31 (1), p.95-103 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273738424 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Biological and medical sciences Chromosome Aberrations Chromosomes, Human, Pair 11 - genetics Chromosomes, Human, Pair 9 - genetics DNA-Binding Proteins - genetics Female Follow-Up Studies Gene Rearrangement Hematologic and hematopoietic diseases Histone-Lysine N-Methyltransferase Humans Karyotyping Leukemia, Myeloid, Acute - classification Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male MDS1 and EVI1 Complex Locus Protein Medical sciences Middle Aged Myeloid-Lymphoid Leukemia Protein - genetics Neoplasm Staging Prognosis Prospective Studies Proto-Oncogenes - genetics Remission Induction Survival Rate Transcription Factors - genetics Translocation, Genetic - genetics Tumors Young Adult |
| title | Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T09%3A27%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deregulated%20Expression%20of%20EVI1%20Defines%20a%20Poor%20Prognostic%20Subset%20of%20MLL-Rearranged%20Acute%20Myeloid%20Leukemias:%20A%20Study%20of%20the%20German-Austrian%20Acute%20Myeloid%20Leukemia%20Study%20Group%20and%20the%20Dutch-Belgian-Swiss%20HOVON/SAKK%20Cooperative%20Group&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=GR%C3%96SCHEL,%20Stefan&rft.date=2013-01-01&rft.volume=31&rft.issue=1&rft.spage=95&rft.epage=103&rft.pages=95-103&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2011.41.5505&rft_dat=%3Cproquest_cross%3E1273738424%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273738424&rft_id=info:pmid/23008312&rfr_iscdi=true |